103438-91-1

Basic information

• Product Name: 3-(Benzyloxy)-4-fluorobenzaldehyde
• Synonyms: 3-(Benzyloxy)-4-fluorobenzaldehyde
• CAS NO: 103438-91-1
• Molecular Formula: C₁₄H₁₁FO₂
• Molecular Weight: 230.2343432
• Mol File: 103438-91-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(Benzyloxy)-4-fluorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Benzyloxy)-4-fluorobenzaldehyde(103438-91-1)
• EPA Substance Registry System: 3-(Benzyloxy)-4-fluorobenzaldehyde(103438-91-1)

Safety Data

• Hazardous Substances Data: 103438-91-1(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 103438-85-3 4-fluoro-3-hydroxybenzaldehyde 
• 100-44-7 benzyl chloride 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 82846-18-2 4?fluoro-3-methoxybenzoic acid 
• 128495-45-4 (4-fluoro-3-methoxy-phenyl)methanol 
• 311464-46-7 4-fluoro-3-nitro-benzaldehyde dimethyl acetal 
• 959251-11-7 3-benzyloxy-4-fluorobenzyl alcohol 

Downstream Products

• 347176-70-9 3-benzyloxy-4-N,N-dimethylaminobenzaldehyde 
• 1401924-70-6 C₁₇H₁₆FNO₄ 
• 1535195-92-6 1-(3-(benzyloxy)-4-fluorobenzyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazine 
• 1426298-30-7 C₁₅H₁₂FNO 
• 123926-57-8 3-benzyloxy-4-fluorobenzyl bromide 
• 1426298-34-1 (4-[¹⁸F]fluoro-m-hydroxyphenethyl)guanidine 
• 1426298-33-0 C₁₅H₁₂⁽¹⁸⁾FNO₃ 
• 347176-77-6 3-benzyloxy-4-[¹⁸F]fluorobenzaldehyde 
• 959251-11-7 3-benzyloxy-4-fluorobenzyl alcohol 

Relevant articles and documents

Macrocyclic compounds and methods for their production

There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.

Sanglifehrin Derivatives and Methods for Their Production

There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.

Novel Dosage Form

There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral admin

NOVEL DOSAGE FORM

There is provided inter alia apharmaceutical dosage form fororal administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral adminis

N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS

Disclosed herein are substantially pure forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, stereoisomer or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.

IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS

Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Synthesis of high-specific-radioactivity 4- and 6-[18F]fluorometaraminol- PET tracers for the adrenergic nervous system of the heart

Fluorine-18 (t12:109.8min)-labeled analogues of metaraminol, 4-[18F]FMR ((1R,2S)-2-amino-1-(4-[18F]fluoro-3-hydroxy phenyl)-1-propanol) and 6-[18F]FMR ((1R,2S)-2-amino-1-(2-[18F]fluoro-5-hydroxyphenyl)-1-propanol), were synthesized as new positron-emission-tomography (PET) tracers for mapping cardiac adrenergic nerve terminals. Copyright

Substituted alkylamine derivatives

The substituted alkylamine derivatives represented by formula (I) STR1 wherein R1 represents (a) substituted or unsubstituted C2-6 alkenyl group, (b) substituted or unsubstituted C3-6 cycloalkenyl group, (c) substituted or unsubstituted C2-6 alkynyl group, (d) substituted or unsubstituted aryl group, (e) substituted or unsubstituted heterocyclic group, (f) fused heterocyclic group which may be substituted, or (g) group represented by the formula Ru11 -Ar wherein R11 is a heterocyclic group and Ar is a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and which may be substituted; STR2 represents a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and may be substituted by R7, X and Y are linking groups, R2 is H or lower alkyl, R3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl or lower cycloalkyl, R4 and R5 are independently hydrogen or halogen atoms, R6 represents (a) substituted or unsubstituted acyclic hydrocarbon group which may be unsaturated, (b) substituted or unsubstituted cycloalkyl group, or (c) substituted or unsubstituted phenyl group, or non-toxic salts thereof. (E)-N-(6-6-dimethyl-2-hepten-4-ynyl)-N-ethyl-3-[4-(3-thienyl)-2-thienyl-methyloxy]benzylamine hydrochloride is a representative example. The substituted alkylamine derivatives are useful as pharmaceuticals, particularly for the treatment and prevention of hypercholesterolemia, hyperlipemia and arteriosclerosis.